Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 7;10:6001. doi: 10.1038/s41598-020-62923-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Clozapine-induced metabolic and behavioral changes in naïve rats. (a) Experimental design for FDG-microPET scans with different doses of clozapine. (b) Timeline of the FDG-microPET scanning procedure. (c) FDG-microPET image after administration of saline (N = 8; 3dClustSim, AFNI, α = 0.05, p < 0.01, k < 39). (d) FDG-microPET image after administration of 1 mg/kg clozapine (N = 8; 3dClustSim, AFNI, α = 0.05, p < 0.01, k < 39). (e) Change in voxel intensity for regional glucose metabolism by dose of CLZ and anatomical location (N = 8; compared with the saline group, 1-way ANOVA with Dunn’s multiple comparisons, *p < 0.05). (f) Representative traces of locomotor activity in the open field test after administration of CLZ. (g) Total distance traveled and (h) mobility in the open field test measured over 30 minutes starting 30 minutes after administration of CLZ or saline (N = 8; 1-way ANOVA with Tukey’s multiple comparisons, *p < 0.05). CLZ, clozapine; L, left; R, right; SN, septal nucleus; TH, thalamus; RN, red nucleus; Hip, hippocampus; Ent, entorhinal cortex.